Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
- Conditions
- Newly Diagnosed and Recurrent Glioblastoma
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT05739942
- Locations
- ๐บ๐ธ
University of California LA, Los Angeles, California, United States
๐บ๐ธUniversity of Colorado Denver, Aurora, Colorado, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Other: Nilotinib
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 222
- Registration Number
- NCT05734053
- Locations
- ๐ฉ๐ช
Novartis Investigative Site, Wuerzburg, Germany
The Belgian REAL (BE.REAL) Registry
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Other: Inclisiran
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT05726838
- Locations
- ๐ง๐ช
Novartis Investigative Site, Yvoir, Belgium
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT05722522
- Locations
- ๐บ๐ธ
IRIS Research and Development, Plantation, Florida, United States
๐บ๐ธMillennium Clinical Trials, Westlake Village, California, United States
๐บ๐ธHealthy Life Research, Miami, Florida, United States
Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 618
- Registration Number
- NCT05714371
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Post Approval Commitment Study on Tabrectaยฎ (Capmatinib) in South Korea
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Other: Capmatinib
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 250
- Registration Number
- NCT05703516
- Locations
- ๐ฐ๐ท
Novartis Investigative Site, Seoul, Korea, Republic of
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France
- Conditions
- Breast Cancer
- Interventions
- Other: ribociclib + ET
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 482
- Registration Number
- NCT05697146
- Locations
- ๐ซ๐ท
Novartis Investigative Site, Villeurbanne, France
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies
- Conditions
- Heterozygous or Homozygous Familial Hypercholesterolemia
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 154
- Registration Number
- NCT05682378
- Locations
- ๐บ๐ธ
Icahn School of Med at Mt Sinai, New York, New York, United States
๐บ๐ธExcel Medical Clinical Trials LLC, Boca Raton, Florida, United States
๐บ๐ธCincinnati Childrens Hospital MC, Cincinnati, Ohio, United States
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Drug: LOU064 (blinded)Drug: placebo
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT05677451
- Locations
- ๐บ๐ธ
Kern Research, Bakersfield, California, United States
๐บ๐ธAllergy and Asthma Medical Group and Research Center, San Diego, California, United States
๐บ๐ธPediatric Dermatology of Miami at the Pediatric CoE, Coral Gables, Florida, United States
Long-term Extension Study of Ligelizumab in Food Allergy
- Conditions
- Food Allergy
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 163
- Registration Number
- NCT05678959
- Locations
- ๐บ๐ธ
UBMD Pediatrics, Buffalo, New York, United States
๐บ๐ธAnn and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
๐บ๐ธFamily Allergy and Asthma, Louisville, Kentucky, United States